Breaking News Instant updates and real-time market news.

NXTC

NextCure

$52.29

-4.27 (-7.55%)

, LLY

Eli Lilly

$138.98

0.97 (0.70%)

15:23
01/13/20
01/13
15:23
01/13/20
15:23

Partnership termination not a negative for NextCure N318, says Piper Sandler

Piper Sandler analyst Edward Tenthoff notes that NextCure (NXTC) disclosed that Eli Lilly (LLY) is terminating an I-O discovery alliance based on the former's FIND-IO platform effective March 3rd. The analyst does not view this termination as a negative for NextCure's existing, wholly-owned antibodies NC318 and NC410 and is a buyer on weakness. Tenthoff adds that NextCure remains a top pick for 2020 ahead of additional NC318 data this year. He reiterates an Overweight rating and $87 price target on NextCure's shares.

NXTC

NextCure

$52.29

-4.27 (-7.55%)

LLY

Eli Lilly

$138.98

0.97 (0.70%)

  • 13

    Jan

  • 27

    Jan

  • 30

    Jan

  • 10

    Feb

NXTC NextCure
$52.29

-4.27 (-7.55%)

11/26/19
BTIG
11/26/19
INITIATION
Target $61
BTIG
Buy
NextCure initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated coverage of NextCure with a Buy rating and $61 price target. The analyst is positive on the company's lead asset, NC318, which has "demonstrated important and rare single-agent activity in early clinical results", as its latest SITC update showed durable activity in IO-refractory NSCLC patients. Hazlett further cites NextCure's efforts to use its technologies in additional "novel IO and immunomodulatory candidates, such as NC410, an anti-LAIR1 IO program that enhances T-cell and dendritic cell activity" expected is to move into the clinic in Q1 of next year. The analyst believes that the "material potential" of NC318 and NextCure's "discovery and development engine" warrants a Buy rating.
12/05/19
NEED
12/05/19
INITIATION
Target $72
NEED
Buy
NextCure initiated with a Buy at Needham
Needham analyst Chad Messer initiated coverage of NextCure with a Buy rating and $72 price target. The company's "validated" technology could represent the next big breakthrough in immuno-oncology, Messer tells investors in a research note. He believes targeting S15 holds the promise of providing benefit to patients who have failed PD-1/PD-L1 blockade. NextCure's lead asset has already achieved human proof-of-concept as a monotherapy in PD-1/PD-L1 inhibitor refractory patients, contends the analyst.
01/06/20
PIPR
01/06/20
NO CHANGE
PIPR
Overweight
NextCure named a top pick for 2020 at Piper Sandler
Piper Sandler analyst Edward Tenthoff named NextCure a top pick for 2020 and reiterates an Overweight rating on the shares with an $87 price target. The analyst expects additional NC318 data this year and says the Phase I data presented at SITC demonstrated clear monotherapy activity.
01/13/20
RHCO
01/13/20
INITIATION
Target $78
RHCO
Buy
NextCure initiated with a Buy at SunTrust
SunTrust analyst Asthika Goonewardene initiated coverage of NextCure with a Buy rating and $78 price target. The analyst cites the potential of the company's lead asset NC318 in immuno-oncology, saying the first data for the program is "reminiscent" of IO's early days. Goonewardene further notes that the "gradual creep" in NextCure is indicative of new investors digesting its investment story and getting into the stock showing positive momentum.
LLY Eli Lilly
$138.98

0.97 (0.70%)

12/18/19
12/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delta Air Lines (DAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying airline stocks are discounting risk from Boeing's (BA) 737 MAX. 2. Eli Lilly (LLY) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying Lilly offers "strong" earnings growth potential and "significant" pipeline optionality from its base as the smallest U.S. Major Pharma with the lowest margins. 3. Sasol (SSL) upgraded to Buy from Neutral at BofA/Merrill. 4. STAG Industrial (STAG) upgraded to Overweight from Neutral at JPMorgan and to Top Pick from Outperform at RBC Capital. 5. Sabra Health Care (SBRA) upgraded to Neutral from Sell at Citi with analyst Nicholas Joseph saying while the skilled nursing environment remains challenged, 2020 earnings growth is now closer to healthcare REIT peers and Sabra's valuation is fairer following the recent underperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/19
STFL
12/20/19
NO CHANGE
STFL
Hold
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
After Lexicon Pharmaceutical (LXRX) announced earlier that sotagliflozin 400 mg achieved the primary endpoint of superiority on A1C reduction versus placebo in the Phase 3 SOTA-EMPA study in type 2 diabetes, Stifel analyst Stephen Willey said he views the inability of sotagliflozin to demonstrate statistically superior HbA1c reduction versus Eli Lilly's (LLY) empagliflozin as a "relative disappointment" and "missed opportunity." The analyst, who had seen this trial as "the best remaining opportunity to establish commercial differentiation" in type 2 diabetes in a crowded field of selective SGLT2i drugs, keeps a Hold rating on Lexicon shares.
12/30/19
ARGS
12/30/19
NO CHANGE
Target $165
ARGS
Buy
Eli Lilly price target raised to $165 from $145 at Argus
Argus analyst David Toung raised his price target on Eli Lilly to $165 and kept his Buy rating, noting the company's FY20 earnings guidance issued earlier this month was stronger than he expected. The analyst also anticipates increased volume and expanded indications for the company's existing drugs supporting its earnings. Toung further cites 2020 benefits for Eli Lilly that include Q3's commercial and regulatory developments such as FDA approval of Reyvow, the additional FDA indication for Taltz, and European Commission's approved update for Trulicity.
01/08/20
PIPR
01/08/20
NO CHANGE
PIPR
Neutral
Eli Lilly still has edge over Blueprint in RET+ lung cancer, says Piper Sandler
After Blueprint Medicines (BPMC) disclosed about 7 months of additional data from the P1/2 ARROW study in patients with RET fusion-positive non-small cell lung cancer, or NSCLC, Piper Sandler analyst Christopher Raymond noted that mDOR was not reached and that CNS response data were not provided. With pralsetinib's durability still not known, he continues to believe Eli Lilly (LLY) "has the edge" in treating later-line NSCLC patients with selpercatinib. Raymond, who prefers "to watch this story play out from the sidelines," maintains a Neutral rating on Blueprint shares.

TODAY'S FREE FLY STORIES

OSTK

Overstock.com

$8.79

-0.25 (-2.77%)

15:45
01/22/20
01/22
15:45
01/22/20
15:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

TER

Teradyne

$73.08

1.55 (2.17%)

15:34
01/22/20
01/22
15:34
01/22/20
15:34
Options
Teradyne options imply 10.2% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CTXS

Citrix

$119.45

1.66 (1.41%)

15:19
01/22/20
01/22
15:19
01/22/20
15:19
Options
Citrix options imply 7.2% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
01/22/20
01/22
15:17
01/22/20
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
01/22/20
01/22
15:16
01/22/20
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$72.03

-7.66 (-9.61%)

15:10
01/22/20
01/22
15:10
01/22/20
15:10
Recommendations
Blueprint Medicines analyst commentary  »

Amendment to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 23

    Jan

JBHT

J.B. Hunt

$114.20

-1.63 (-1.41%)

15:09
01/22/20
01/22
15:09
01/22/20
15:09
Hot Stocks
J.B. Hunt raises quarterly dividend to 27c from 26c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

TXN

Texas Instruments

$133.23

2.38 (1.82%)

15:04
01/22/20
01/22
15:04
01/22/20
15:04
Options
Texas Instruments options imply 7.4% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

QSR

Restaurant Brands

$65.41

0.085 (0.13%)

, TAST

Carrols Restaurant

$5.01

-0.1 (-1.96%)

14:55
01/22/20
01/22
14:55
01/22/20
14:55
Periodicals
Burger King cutting Impossible Whopper price as sales slow, Bloomberg says »

Burger King, a Restaurant…

QSR

Restaurant Brands

$65.41

0.085 (0.13%)

TAST

Carrols Restaurant

$5.01

-0.1 (-1.96%)

BYND

Beyond Meat

$124.60

-4.64 (-3.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$4.96

0.81 (19.52%)

14:51
01/22/20
01/22
14:51
01/22/20
14:51
Recommendations
Express analyst commentary  »

Wedbush…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

BYND

Beyond Meat

$125.41

-3.83 (-2.96%)

, QSR

Restaurant Brands

$65.43

0.105 (0.16%)

14:51
01/22/20
01/22
14:51
01/22/20
14:51
Periodicals
Burger King cutting Impossible Whopper price as sales slow, Bloomberg says »

Shares of Beyond Meat,…

BYND

Beyond Meat

$125.41

-3.83 (-2.96%)

QSR

Restaurant Brands

$65.43

0.105 (0.16%)

TAST

Carrols Restaurant

$5.02

-0.09 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$21.04

0.11 (0.53%)

14:49
01/22/20
01/22
14:49
01/22/20
14:49
Options
Kinder Morgan options imply 2.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

VZ

Verizon

$60.68

0.36 (0.60%)

, GOOG

Alphabet

$1,493.50

8.58 (0.58%)

14:43
01/22/20
01/22
14:43
01/22/20
14:43
Hot Stocks
Verizon partners with Google Stadia for cloud gaming »

"It's no…

VZ

Verizon

$60.68

0.36 (0.60%)

GOOG

Alphabet

$1,493.50

8.58 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 03

    Feb

MDC

M.D.C. Holdings

$43.74

0.51 (1.18%)

14:39
01/22/20
01/22
14:39
01/22/20
14:39
Hot Stocks
Richmond American Homes plans to acquire 1,000 sites at Aurora Highlands »

Richmond American Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

CHCO

City Holding

$80.65

0.14 (0.17%)

14:32
01/22/20
01/22
14:32
01/22/20
14:32
Hot Stocks
City Holding announces pre-tax gain of $17.8M on sale of Visa Class B shares »

City Holding Company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$66.49

0.19 (0.29%)

14:31
01/22/20
01/22
14:31
01/22/20
14:31
Hot Stocks
Comerica names Melinda Chausse chief credit officer »

Comerica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Feb

AAOI

Applied Optoelectronics

$14.23

0.51 (3.72%)

14:25
01/22/20
01/22
14:25
01/22/20
14:25
Options
Applied Optoelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$126.65

0.54 (0.43%)

, UNP

Union Pacific

$181.23

-1.27 (-0.70%)

14:22
01/22/20
01/22
14:22
01/22/20
14:22
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$126.65

0.54 (0.43%)

UNP

Union Pacific

$181.23

-1.27 (-0.70%)

KMB

Kimberly-Clark

$145.50

0.91 (0.63%)

VFC

VF Corp.

$95.12

0.49 (0.52%)

LUV

Southwest

$53.64

0.1 (0.19%)

MTB

M&T Bank

$162.54

1.655 (1.03%)

KEY

KeyCorp

$19.61

0.11 (0.56%)

HBAN

Huntington Bancshares

$14.84

0.22 (1.51%)

AAL

American Airlines

$27.50

0.29 (1.07%)

JBLU

JetBlue

$19.90

0.81 (4.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 17

    Feb

  • 04

    Mar

TXN

Texas Instruments

$133.66

2.81 (2.15%)

, KMI

Kinder Morgan

$21.05

0.12 (0.57%)

14:22
01/22/20
01/22
14:22
01/22/20
14:22
Earnings
Notable companies reporting after market close »

Notable companies…

TXN

Texas Instruments

$133.66

2.81 (2.15%)

KMI

Kinder Morgan

$21.05

0.12 (0.57%)

CTXS

Citrix

$119.46

1.67 (1.42%)

TER

Teradyne

$73.17

1.64 (2.29%)

PTC

PTC

$79.86

0.93 (1.18%)

STLD

Steel Dynamics

$32.05

0.14 (0.44%)

SLM

Sallie Mae

$9.15

0.31 (3.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 29

    Jan

  • 12

    Feb

  • 26

    Feb

XOM

Exxon Mobil

$67.01

-0.58 (-0.86%)

14:17
01/22/20
01/22
14:17
01/22/20
14:17
Periodicals
Exxon Mobil set to kick off U.K., Germany asset sales, Bloomberg says »

Exxon Mobil intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

CHEOY

Cochlear

$0.00

(0.00%)

14:17
01/22/20
01/22
14:17
01/22/20
14:17
Downgrade
Cochlear rating change  »

Cochlear downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
01/22/20
01/22
14:17
01/22/20
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
01/22/20
01/22
14:16
01/22/20
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPG

Simon Property

$146.15

-2.96 (-1.99%)

14:15
01/22/20
01/22
14:15
01/22/20
14:15
Options
Simon Property put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

FCEL

FuelCell

$2.15

-0.725 (-25.26%)

, PKX

Posco

$51.39

-0.15 (-0.29%)

14:14
01/22/20
01/22
14:14
01/22/20
14:14
On The Fly
FuelCell plunges on bigger than expected loss, revenue miss »

Shares of FuelCell (FCEL)…

FCEL

FuelCell

$2.15

-0.725 (-25.26%)

PKX

Posco

$51.39

-0.15 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 31

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.